Novartis Phase III study shows ACZ885 (canakinumab) reduces cardiovascular risk in people who survived a heart attack
(WorldNews Switzerland)

Phase III CANTOS study met the primary endpoint, a composite of heart attack, stroke and cardiovascular death, showing that ACZ885 (canakinumab) in combination with standard of care therapy reduces cardiovascular risk in people with a prior heart attack and inflammatory atherosclerosis Despite current treatments about 40% of heart attack survivors remain at increased risk of recurrent heart attack, stroke or cardiovascular death because of high-risk inflammatory atherosclerosis[1]; 25% experience another event within five years[2] Full results will be presented at an upcoming medical congress; Novartis plans to initiate discussions with regulatory authorities Basel, June 22, 2017 - Novartis...